[Effects of flecainide in patients with non-sustained ventricular tachycardia and impaired left ventricular function].
Anti-arrythmia efficacy and effects on left ventricular function of flecainide have been evaluated in 9 patients with symptomatic non sustained ventricular tachycardia (NSVT) and left ventricular ejection fraction (LVEF) lower than 30%, respectively detected by Holter monitoring and radionuclide angiocardiography in basal conditions. Seven to eleven days after starting flecainide therapy (100 mg b.i.d.), Holter and radionuclide angiocardiography were repeated. In 56% of patients a ventricular premature beats (VPB) reduction more than 70% was obtained and total VPB suppression was achieved in 33% of patients. Total suppression of NSVT was obtained in 67% of patients; LVEF did not show significant changes. Thus, antiarrhythmic efficacy of flecainide resulted in agreement with the previous reports, whereas no patient developed signs or symptoms of heart failure or pro-arrhythmia.
De Marzio
P
P
Istituto di Clinica Medica, Università degli Studi di Roma La Sapienza.
Morelli
S
S
Suppa
M
M
Caputo
V
V
Mango
L
L
Guido
V
V
Cardoni
F
F
Gnecchi
M
M
Aguglia
F
F
D000368:Aged; D004341:Drug Evaluation; D005260:Female; D005424:Flecainide / Q000627:therapeutic use*; D006352:Heart Ventricles; D006801:Humans; D008297:Male; D008875:Middle Aged; D013318:Stroke Volume; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology
D005424:Flecainide
Effetti della flecainide in pazienti con tachicardia ventricolare non sostenuta e ridotta funzione ventricolare sinistra.